Acute myeloid leukaemia (AML) is a haematological cancer with dismal survival rates in children. A major limitation of AML treatment is the off-target toxicity of current chemotherapeutic therapies. Consequently, there is a need to identify molecular targets which are specific to AML and absent in healthy cells, allowing for a precision medicine approach to treat the disease. Long non-coding RNAs (lncRNAs) are a class of RNAs which have unique expression profiles in multiple cancers, including AML.
Targeting lncRNAs therapeutically is a rapidly emerging field and presents an opportunity to specifically eradicate AML cells. Therefore, the aims of this project are to identify lncRNAs that are both specific and vital for AML cells and explore their potential as therapeutic targets.
How to Apply
Express your interest in this project by emailing Professor Richard Lock. Include a copy of your CV and your academic transcript(s).
School / Research Area
Clinical Medicine
- Overview
- News
- Our team
- References